amifostine
Sign in to saveAlso known as Ethyol, Gammaphos, Apaetp, Ethiofos, Aminopropylaminoethyl Thiophosphate, SAPEP, Amifostina, Amifostinum
Amifostine (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Research
2,067 papers- Advances of Amifostine in Radiation Protection: Administration and Delivery.Molecular pharmaceutics · 2023
- Amifostine.Cancer biotherapy & radiopharmaceuticals · 1999
- Use of Amifostine for Cytoprotection during Radiation Therapy: A Review.Oncology · 2020
- Amifostine: the first selective-target and broad-spectrum radioprotector.The oncologist · 2007
- Amifostine and chemotherapy-related thrombocytopenia.Seminars in oncology · 1996
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 214.054
- Has use
- medication
Show 4 more facts
- chemical formula
- C₅H₁₅N₂O₃PS
- canonical SMILES
- C(CN)CNCCSP(=O)(O)O
- World Health Organisation international non-proprietary name
- amifostine
- defined daily dose
- 1.7
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Indications
- Pharmacokinetics
- Mechanism of action
- Adverse effects
- Contraindications
- References
Amifostine (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
==Indications== Amifostine is used therapeutically to reduce the incidence of neutropenia-related fever and infection induced by DNA-binding chemotherapeutic agents including alkylating agents (e.g. cyclophosphamide) and platinum-containing agents (e.g. cisplatin). It is also used to decrease the cumulative nephrotoxicity associated with platinum-containing agents. Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer.
Excerpted from Wikipedia’s “amifostine” article, available under the CC BY-SA 4.0 licence.